NCT03154996 is a Phase 1 clinical trial of Topotecan in Gliomas, sponsored by Jeffrey N. Bruce.

Who is sponsoring NCT03154996?

NCT03154996 is sponsored by Jeffrey N. Bruce.

What drugs are being tested in NCT03154996?

Interventions in NCT03154996: Topotecan, Gadolinium, Synchromed II infusion pumps.

Is NCT03154996 still recruiting?

NCT03154996 is currently completed. Last updated 5 July 2022.

Last reviewed 2022-07-05 · How we verify

NCT03154996

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chronic Convection Enhanced Delivery of Topotecan

Completed Phase 1 Last updated 5 July 2022

What this trial tests

Phase 1 trial testing Topotecan in Gliomas in 5 participants. Completed in 20 August 2021.

Timeline

18 January 2018

Primary endpoint
20 August 2021

20 August 2021

Quick facts

Lead sponsor	Jeffrey N. Bruce
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	5
Start date	18 January 2018
Primary completion	20 August 2021
Estimated completion	20 August 2021
Sites	1 location across United States

Drugs / interventions tested

Topotecan (topotecan) — full drug profile →
Gadolinium (GADOLINIUM) — full drug profile →
Synchromed II infusion pumps

Conditions studied

Gliomas — all drugs for Gliomas →

Sponsor

Jeffrey N. Bruce

Who can join

18 and older, any sex, with Gliomas. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary goal of this study is to establish, for the first time, safety of prolonged intracerebral convection enhanced delivery of chemotherapy in patients with recurrent high grade glioma (HGG). Secondary objectives will include determination of topotecan (TPT) distribution and radiographic tumor response with prolonged continuous intracerebral convection-enhanced delivery (CED).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Convection-enhanced drug delivery for glioblastoma: a review.
D'Amico RS, Aghi MK, Vogelbaum MA, Bruce JN. · · 2021 · cited 116× · PMID 33611708 · DOI 10.1007/s11060-020-03408-9
Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial.
Spinazzi EF, Argenziano MG, Upadhyayula PS, Banu MA, et al · · 2022 · cited 66× · PMID 36243020 · DOI 10.1016/s1470-2045(22)00599-x
Addressing BBB Heterogeneity: A New Paradigm for Drug Delivery to Brain Tumors.
Griffith JI, Rathi S, Zhang W, Zhang W, et al · · 2020 · cited 47× · PMID 33322488 · DOI 10.3390/pharmaceutics12121205
Breaching the Blood-Brain Tumor Barrier for Tumor Therapy.
Marcucci F, Corti A, Ferreri AJM. · · 2021 · cited 30× · PMID 34063335 · DOI 10.3390/cancers13102391
Research progress of anti-glioma chemotherapeutic drugs (Review).
Zhou YS, Wang W, Chen N, Wang LC, et al · · 2022 · cited 23× · PMID 35362540 · DOI 10.3892/or.2022.8312
Convection-enhanced delivery for high-grade glioma.
Kang JH, Desjardins A. · · 2022 · cited 21× · PMID 35096401 · DOI 10.1093/nop/npab065
Convection Enhanced Delivery in the Setting of High-Grade Gliomas.
Nwagwu CD, Immidisetti AV, Jiang MY, Adeagbo O, et al · · 2021 · cited 15× · PMID 33921157 · DOI 10.3390/pharmaceutics13040561
Anatomical Targeting of Anticancer Drugs to Solid Tumors Using Specific Administration Routes: Review.
Saito A, Kitayama J, Nagai R, Aizawa K. · · 2023 · cited 11× · PMID 37376112 · DOI 10.3390/pharmaceutics15061664

Verify or expand the search:

Other trials of Topotecan

Trials testing the same drug.

NCT07437963 — Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatmen · Phase 1, PHASE2 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
NCT07321912 — Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma · Phase 2 · not yet recruiting
NCT06425419 — The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy · Phase 1 · not yet recruiting

Other recruiting trials for Gliomas

Currently open trials in the same condition.

NCT07374692 — Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors · NA · recruiting
NCT07198256 — AI-assisted Diagnosis of Malignant Brain Tumors · recruiting
NCT06828341 — A Single-arm, Open, Exploratory Clinical Study of Allogeneic CAR-T Cells in the Treatment of Relapsed/Refractory Brain G · EARLY_PHASE1 · recruiting
NCT05804227 — Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas · EARLY_PHASE1 · recruiting
NCT06736470 — Surgical Suction Aspirates Fluorescence Measurement · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03154996 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jeffrey N. Bruce
Last refreshed: 5 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03154996.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing